These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12389798)

  • 1. Teaching patients to self-inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications.
    Mohr DC; Cox D; Epstein L; Boudewyn A
    J Behav Ther Exp Psychiatry; 2002 Mar; 33(1):39-47. PubMed ID: 12389798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications.
    Mohr DC; Cox D; Merluzzi N
    Mult Scler; 2005 Apr; 11(2):182-5. PubMed ID: 15794392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis.
    Cox D; Stone J
    J Neurosci Nurs; 2006 Jun; 38(3):167-71. PubMed ID: 16817668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject.
    Mohr DC; Boudewyn AC; Likosky W; Levine E; Goodkin DE
    Ann Behav Med; 2001; 23(2):125-32. PubMed ID: 11394554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Teaching intramuscular self-injection in patients with multiple sclerosis reaching interferon beta-1a: evaluation of a descriptive multicenter program].
    Visy JM; Gentin M; Bazerque C;
    Presse Med; 2007 Jun; 36(6 Pt 1):841-50. PubMed ID: 17482792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study.
    Wray S; Armstrong R; Herrman C; Calkwood J; Cascione M; Watsky E; Hayward B; Mercer B; Dangond F
    Expert Opin Drug Deliv; 2011 Dec; 8(12):1543-53. PubMed ID: 22032264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis.
    Fraser C; Hadjimichael O; Vollmer T
    J Neurosci Nurs; 2001 Oct; 33(5):231-9. PubMed ID: 11668881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depression, anxiety and stress severities in multiple sclerosis patients using injectable versus oral treatments.
    Al-Hussain F; Al-Salloum N; Alazwary N; Saeedi J; Howaidi S; Daif A
    J Comp Eff Res; 2017 Jul; 6(5):405-412. PubMed ID: 28699780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
    Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
    J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
    Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
    Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
    Bayas A; Ouallet JC; Kallmann B; Hupperts R; Fulda U; Marhardt K;
    Expert Opin Drug Deliv; 2015 Aug; 12(8):1239-50. PubMed ID: 26098143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Kira J; Ueno Y; Harada N; Hirakata T
    Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open trial with cognitive behavioral therapy for blood- and injection phobia in pregnant women-a group intervention program.
    Lilliecreutz C; Josefsson A; Sydsjö G
    Arch Womens Ment Health; 2010 Jun; 13(3):259-65. PubMed ID: 19859788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.
    Lugaresi A; De Robertis F; Clerico M; Brescia Morra V; Centonze D; Borghesan S; Maniscalco GT;
    Expert Opin Drug Deliv; 2016 Jul; 13(7):931-5. PubMed ID: 26909646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.
    Zecca C; Disanto G; Mühl S; Gobbi C
    BMC Neurol; 2017 Sep; 17(1):171. PubMed ID: 28870152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cognitive behavioral therapy with relaxation vs. imagery rescripting on test anxiety: A randomized controlled trial.
    Reiss N; Warnecke I; Tolgou T; Krampen D; Luka-Krausgrill U; Rohrmann S
    J Affect Disord; 2017 Jan; 208():483-489. PubMed ID: 27825724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
    Devonshire VA; Feinstein A; Moriarty P
    BMC Res Notes; 2016 Mar; 9():148. PubMed ID: 26951043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study.
    Ghezzi A; Bianchi A; Baroncini D; Bertolotto A; Malucchi S; Bresciamorra V; Lanzillo R; Milani N; Martinelli V; Patti F; Chisari C; Rottoli M; Simone M; Paolicelli D; Visconti A;
    Neurol Sci; 2017 Nov; 38(11):1999-2005. PubMed ID: 28831635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis.
    Mohr DC; Likosky W; Bertagnolli A; Goodkin DE; Van Der Wende J; Dwyer P; Dick LP
    J Consult Clin Psychol; 2000 Apr; 68(2):356-61. PubMed ID: 10780138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.